Dr Reddy’s taps Fresenius Kabi for exclusive US commercialization of rituximab biosimilar
Reuters2026/08/03 10:25- Dr. Reddy’s signed a US commercialization agreement granting Fresenius Kabi exclusive rights to market its rituximab biosimilar.
- The deal follows FDA clearance for the product, positioning Fresenius Kabi to lead the US launch while Dr. Reddy’s supplies from its Hyderabad biologics site.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
For the first time in over a year, the open interest share of altcoins has surpassed that of bitcoin.
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
Crypto prices
More
